Search

everythinglearnresearchcommunity

for

Search:↓

Diphenylcyclopropenone is effective and safe for treating severe alopecia areata in children, with maintenance therapy reducing relapse risk.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Combining cetirizine and topical steroids can effectively manage severe lichen planus pilaris.

The new delivery method for dutasteride is more effective and has fewer side effects.

The new gel for hair loss is safe, effective, and reduces side effects.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Triptolide effectively and safely reduces actinic keratosis lesions in mice.

Early detection and stopping the drug are key to managing DRESS, and careful monitoring is important due to possible severe reactions.

Certain cancer drugs can cause skin issues like rashes and itching.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Co-trimoxazole successfully treated a girl with multiple autoimmune symptoms.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Glucocorticoid corticosteroids improve muscle strength in Duchenne muscular dystrophy but can cause side effects.

Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.

Non-biologic immunosuppressive drugs are crucial for treating autoimmune and chronic inflammatory skin diseases.

P-3074 effectively blocks scalp DHT better than oral finasteride.

KX-826 is safe and effectively increases hair count in men with hair loss.

Brodalumab effectively treated a man's severe hand and foot psoriasis.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

A patient's grey hair regained color during treatment with adalimumab.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.